A Rejection From AstraZeneca, and a Pounding on WWE
In the "Movers and Shakers" segment of today's Investor Beat, Chris Hill and Fool analyst Taylor Muckerman wade through AstraZenaca, FireEye, and World Wrestling Entertainment.
Taylor outlines the problems investors feel about AstraZeneca's recent rejection of Pfizer's $117 billion bid. With political backlash in the U.K. from such a large potential acquisition and Pfizer's poor track record with acquisitions, Taylor explores why investors might be upset about this deal and rejection. He sees the stock, however, with a turnaround in the future as new products come out.
After a rejected bid, Chris and Taylor talk about FireEye's stock rise today after the security software company's lock-up period expires on Wednesday, yet Chris notes that the year has been pretty rough for FireEye. Taylor explains that the expiring lock-up will give investors insights into what insiders think of the company and he thinks that this could be good for the investors to take notice.
Then, Chris and Taylor explore the continued dip of World Wrestling Entertainment. Chris explores what management offered investors today -- with a Netflix-like offering to their viewers -- yet he's wary about how many subscribers they'll be able to find in the short term.
Are you ready to profit from this $14.4 trillion revolution?
Every investor wants to get in on revolutionary ideas before they hit it big -- like buying PC maker Dell in the late 1980s, before the consumer computing boom, or purchasing stock in e-commerce pioneer Amazon.com in the late 1990s, when it was nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hypergrowth markets. The real trick is to find a small-cap "pure play" and then watch as it grows in explosive fashion within its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.
The article A Rejection From AstraZeneca, and a Pounding on WWE originally appeared on Fool.com.Chris Hill owns shares of Amazon.com. Taylor Muckerman has no position in any stocks mentioned. The Motley Fool recommends Amazon.com and Netflix. The Motley Fool owns shares of Amazon.com and Netflix. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.